12/29/2025

Janusmed kön och genus

Janusmed kön och genus – Fortum

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ceftazidim

Ceftazidim

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Sommers DK, Walters L, Van Wyk M, Harding SM, Paton AM, Ayrton J. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983;23:892-6.

  2. Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol. 2007;64:27-35.

  3. Getachew H, Tadesse Y, Shibeshi W. Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. BMC Nephrol. 2015;16:158.

  4. Nathorst-Böös J, Philipson A, Hedman A, Arvisson A. Renal elimination of ceftazidime during pregnancy. Am J Obstet Gynecol. 1995;172:163-6.

  5. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother. 1998;10:35-46.

  6. Lee DS, Choe HS, Kim HY, Yoo JM, Bae WJ, Cho YH et al. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis. 2016;51:89-96.

  7. Mohammed OA, Abubakr KT, Yaghoobi A, Khdhir HH, Ali DH, Abdalrahman PK et al. Microbial prevalence and understanding of their antimicrobial susceptibility in urinary tract of patients attending at shar teaching hospital (2018-2022). BMC Res Notes. 2025;18(1):329.

  8. Mostafavi SN, Rostami S, Rezaee Nejad Y, Ataei B, Mobasherizadeh S, Cheraghi A et al. Antimicrobial Resistance in Hospitalized Patients with Community Acquired Urinary Tract Infection in Isfahan, Iran. Arch Iran Med. 2021;24(3):187-192.

  9. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.

  10. Gesu GP, Marchetti F. Increasing resistance according to patient's age and sex in Escherichia coli isolated from urine in Italy. J Chemother. 2007;19(2):161-5.

  11. Asai Y, Yamamoto T, Abe Y. Evaluation of the Expression Profile of Antibiotic-Induced Thrombocytopenia Using the Japanese Adverse Drug Event Report Database. Int J Toxicol. 2021;40(6):542-550.

  1. Sommers DK, Walters L, Van Wyk M, Harding SM, Paton AM, Ayrton J. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983;23:892-6.
  2. Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol. 2007;64:27-35.
  3. Getachew H, Tadesse Y, Shibeshi W. Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. BMC Nephrol. 2015;16:158.
  4. Nathorst-Böös J, Philipson A, Hedman A, Arvisson A. Renal elimination of ceftazidime during pregnancy. Am J Obstet Gynecol. 1995;172:163-6.
  5. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother. 1998;10:35-46.
  6. Lee DS, Choe HS, Kim HY, Yoo JM, Bae WJ, Cho YH et al. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis. 2016;51:89-96.
  7. Mohammed OA, Abubakr KT, Yaghoobi A, Khdhir HH, Ali DH, Abdalrahman PK et al. Microbial prevalence and understanding of their antimicrobial susceptibility in urinary tract of patients attending at shar teaching hospital (2018-2022). BMC Res Notes. 2025;18(1):329.
  8. Mostafavi SN, Rostami S, Rezaee Nejad Y, Ataei B, Mobasherizadeh S, Cheraghi A et al. Antimicrobial Resistance in Hospitalized Patients with Community Acquired Urinary Tract Infection in Isfahan, Iran. Arch Iran Med. 2021;24(3):187-192.
  9. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.
  10. Gesu GP, Marchetti F. Increasing resistance according to patient's age and sex in Escherichia coli isolated from urine in Italy. J Chemother. 2007;19(2):161-5.
  11. Asai Y, Yamamoto T, Abe Y. Evaluation of the Expression Profile of Antibiotic-Induced Thrombocytopenia Using the Japanese Adverse Drug Event Report Database. Int J Toxicol. 2021;40(6):542-550.